Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), has completed its $16.5 billion, all-cash acquisition of contract development and manufacturing firm Catalent (CLCT), the companies said on Wednesday.
Under terms of the transaction, Catalent shareholders received $63.50 in cash for each of their share, a premium of around 47.5% to the volume-weighted average price of the stock prior to the deal being announced in early February.
Catalent shares stopped trading on Wednesday and are being delisted from the New York Stock Exchange, the companies said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。